Bridgewater Advisors Inc. Purchases New Shares in Thermo Fisher Scientific Inc. (NYSE:TMO)

Bridgewater Advisors Inc. purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,210 shares of the medical research company’s stock, valued at approximately $1,100,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $25,000. Ameriflex Group Inc. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $30,000. Cassady Schiller Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 89.2% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 33 shares during the period. VSM Wealth Advisory LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $36,000. Finally, Navigoe LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $37,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.33% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on TMO shares. Barclays cut their target price on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating on the stock in a report on Tuesday, June 24th. Evercore ISI decreased their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Royal Bank Of Canada dropped their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, April 24th. Finally, The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Wednesday, April 23rd. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $600.30.

Thermo Fisher Scientific Stock Down 1.4%

TMO opened at $428.70 on Tuesday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a 50 day moving average of $409.45 and a 200 day moving average of $475.17. The company has a market cap of $161.83 billion, a PE ratio of 25.14, a price-to-earnings-growth ratio of 2.31 and a beta of 0.77. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period last year, the company earned $5.11 EPS. Thermo Fisher Scientific’s revenue for the quarter was up .2% on a year-over-year basis. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.